- Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
- Denali Therapeutics Announces $500 million Private Placement Equity Financing
- Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
- Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
- Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
- Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
- Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023
- Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
More ▼
Key statistics
On Friday, Denali Therapeutics Inc (DNLI:NSQ) closed at 16.00, 3.56% above its 52-week low of 15.45, set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.50 |
---|---|
High | 16.80 |
Low | 15.92 |
Bid | 16.00 |
Offer | 16.86 |
Previous close | 16.60 |
Average volume | 1.11m |
---|---|
Shares outstanding | 142.40m |
Free float | 125.95m |
P/E (TTM) | -- |
Market cap | 2.36bn USD |
EPS (TTM) | -1.09 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 21:00 BST.
More ▼